全文获取类型
收费全文 | 18787篇 |
免费 | 1688篇 |
国内免费 | 10篇 |
专业分类
20485篇 |
出版年
2022年 | 134篇 |
2021年 | 218篇 |
2020年 | 145篇 |
2019年 | 194篇 |
2018年 | 241篇 |
2017年 | 239篇 |
2016年 | 340篇 |
2015年 | 704篇 |
2014年 | 769篇 |
2013年 | 970篇 |
2012年 | 1189篇 |
2011年 | 1238篇 |
2010年 | 812篇 |
2009年 | 769篇 |
2008年 | 1038篇 |
2007年 | 1134篇 |
2006年 | 1053篇 |
2005年 | 1056篇 |
2004年 | 1036篇 |
2003年 | 861篇 |
2002年 | 867篇 |
2001年 | 281篇 |
2000年 | 239篇 |
1999年 | 262篇 |
1998年 | 282篇 |
1997年 | 168篇 |
1996年 | 144篇 |
1995年 | 129篇 |
1994年 | 145篇 |
1993年 | 133篇 |
1992年 | 175篇 |
1991年 | 157篇 |
1990年 | 142篇 |
1989年 | 171篇 |
1988年 | 122篇 |
1987年 | 148篇 |
1986年 | 121篇 |
1985年 | 144篇 |
1984年 | 132篇 |
1983年 | 125篇 |
1982年 | 139篇 |
1981年 | 125篇 |
1980年 | 105篇 |
1979年 | 100篇 |
1978年 | 88篇 |
1977年 | 100篇 |
1976年 | 81篇 |
1974年 | 96篇 |
1973年 | 83篇 |
1972年 | 70篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
62.
Arthur Leznoff Harold Frank Paul Telner Jacob Rosensweig J. Leonard Brandt 《CMAJ》1964,91(22):1154-1160
Although Montreal is in an endemic area, significant clinical histoplasmosis with systemic manifestations has been, until recently, infrequently diagnosed. However, since the autumn of 1963, 31 cases of clinically significant histoplasmosis have been seen by the authors. These were divided into two groups: (1) patients in whom the diagnosis was established on the basis of histological and/or cultural demonstration of the fungus; (2) patients in whom the diagnosis was based on a positive histoplasmin skin test, a complement fixation antibody titre of 1:32 or greater and compatible clinical and radiological findings. An additional group of 11 patients who presented with erythema multiforme was investigated and a heretofore unrecognized relationship between histoplasmosis and erythema multiforme was established. 相似文献
63.
64.
65.
66.
67.
Influence of age and sex on exercise cardiac output 总被引:3,自引:0,他引:3
M R Becklake H Frank G R Dagenais G L Ostiguy C A Guzman 《Journal of applied physiology》1965,20(5):938-947
68.
Benjamin B. Roa Frank Greenberg Preethi Gunaratne Christine M. Sauer Mark S. Lubinsky Chahira Kozma Jeanne M. Meck R. Ellen Magenis Lisa G. Shaffer J. R. Lupski 《Human genetics》1996,97(5):642-649
Autosomal dominant Charcot-Marie-Tooth type-1A neuropathy (CMT1A) is a demyelinating peripheral nerve disorder that is commonly
associated with a submicroscopic tandem DNA duplication of a 1.5-Mb region of 17p11.2p12 that contains the peripheral myelin
gene PMP22. Clinical features of CMT1A include progressive distal muscle atrophy and weakness, foot and hand deformities, gait abnormalities,
absent reflexes, and the completely penetrant electrophysiologic phenotype of symmetric reductions in motor nerve conduction
velocities (NCVs). Molecular and fluorescence in situ hybridization (FISH) analyses were performed to determine the duplication
status of the PMP22 gene in four patients with rare cytogenetic duplications of 17p. Neuropathologic features of CMT1A were seen in two of these
four patients, in addition to the complex phenotype associated with 17p partial trisomy. Our findings show that the CMT1A
phenotype of reduced NCV is specifically associated with PMP22 gene duplication, thus providing further support for the PMP22 gene dosage mechanism for CMT1A.
Received: 3 May 1995 / Revised: 1 August 1995 相似文献
69.
70.
Foreign and self endogenous proteins can be processed and presented as peptides bound to class I and II MHC to CD8 or CD4-positive T cells. In the case of mutant tumor suppressor proteins, proteosomal processing of the mutant protein could occur either in the tumor cell or in an antigen-presenting cell to generate a variety of peptides that can be transported into the endoplasmic reticulum and loaded on the MHC. These peptides may induce tumor suppressor specific T cells in the presence of sufficient T help and costimulation. In human cancer, p53 is frequently found to be both somatically mutant and overexpressed. We and others are currently investigating the potential of peptide-induced cellular immunotherapy to induce cytotoxic T cells to peptides containing point mutant p53, or other oncogene products, thus potentially inducing tumor-specific cellular immunity. There are many potential prerequisites for successful immunotherapeutic targeting of intracellular antigens such as p53, including: (1) the protein must have a sufficient expression level; (2) it should be a candidate for proteolytic degradation and transport into the ER; (3) the tumor-specific epitope must have adequate affinity to the corresponding MHC restriction element; (4) the MHC complex must be expressed at sufficient levels on the cell surface to make the tumor-specific epitope accessible to T cells; and (5) the method of therapeutic immunization must effectively induce oncopeptide-specific cytotoxic T lymphocytes. 相似文献